CEO Message

NEORNAT Inc. is a company that researches the role and function of RNA in the occurrence and metastasis of cancer, identifies new anticancer mechanisms, and researches and develops RNA-based anticancer drugs that target it.

For a long time, RNA has been attracting attention only for its role in transcribing proteins in vivo based on DNA, but recently, it has been reported that numerous non-coding RNAs that are not involved in protein transcription have a meaningful effect on the editing or expression of other genes. We aim to become a leading company in the development of RNA therapeutics that selectively target RNA or RNA network control mechanisms for diseases, particularly cancer, with high-level research as the source technology. The main research areas are macrophage immuno-oncology drugs, which have not been identified so far, and RNA regulator-targeted anti-cancer drugs. In addition, we are developing a diagnostic kit that enables early liver cancer treatment by discovering the world's first whole-cycle liver disease diagnostic multiple markers using big data-based liver cancer diagnosis technology that we have built for many years, enabling early liver cancer diagnosis.

With these efforts and achievements, NEORNAT Inc. promises to contribute to human health and quality of life.

NEORNAT Inc. CEO Suk Woo Nam

Company Identity

NEORNAT Inc. is a company that researches and develops first-in-class anticancer drugs that target RNA regulators.

NEORNAT

=

Neo (The New)

+

RNA + T (Therapy)

The New RNA Therapeutics Company
First-in-Class Target Therapeutics

History

2023

01
Published an article on Experimental & Molecular Medicine (IF: 12.153) : ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer

2022

11
Selected as Korea Angel Investment TIPS
09
Established R&D Center (located in Banpo-dong, Seocho-gu)
06
Steintech Bio Season 1, Final Round Top 5 Selection and Best Company Selection
Published an article on Experimental & Molecular Medicine (IF: 12.153) : hnRNPC induces isoform shifts in miR-21-5p leading to cancer development
03
Completed pre-round Series A investment

2021

12
Signed out of license out with KPS Co., Ltd. for liver cancer diagnosis/analysis technology
Catholic University Industry-University Cooperation Foundation- NEORNAT Inc. transfers 3 technologies for new drug development
08
Published in Oncogene (IF:9.867) paper
07
Selected as Korea Angel Investment TIPS
04
Selected as a 3-year project for the disease-centered translational research project
01
Shinhan Capital Investment Attraction

2020

11
Catholic University Industry-University Cooperation Foundation - Completed technology transfer for 4 cases of NEORNAT Inc.
10
Selected as K-BIC STAR (New drug development start-up company, Korea Health Industry Promotion Agency)
09
Completed attracting angel investment
Established NEORNAT Inc.

People

CEO Suk Woo Nam

Professor, Dept of Pathology, College of Medicine,
The Catholic Univ. of Korea
Director, Functional RNomics Research Center (FRRC),
The Catholic Univ. of Korea
Associate Editor, Biomolecules
Advisory Editorial Board, Molecular & Cellular Toxicology
Advisory Editorial Board, Archives of Pharmacal Research
Member, American Associate for Cancer Research
Member, National Academy of Medicine of Korea
Member, The Korean Cancer Association
Member, The Pharmaceutical Society of Korea
Member, Korea Genome Organization

CSO&CDD Ki Ho Moon

30 years of pharmaceutical industry experience
(New drug research, Clinical development, Marketing)
Graduated from the Department of Pharmacy and Graduate School of Pharmacy, Sungkyunkwan University

Leader Hee Doo Yang

Lab of Cancer RNA Biology
Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
Specialty: RNA variation and functional study in tumor immunity
SCI paper: 11, Patent: 5

Leader Sang Yean Kim

Lab of Cancer RNA Biology
Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
Specialty: cancer RNA variation and functional study
SCI paper: 7, Patent: 3

Leader Jung Hwan Yoon

Research Lecturer, The Department of Pathology, The Catholic University, South Korea
Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
Specialty: Carcinogenesis and progression mechanism study in gastric cancer
SCI paper: 50, Patent: 13

Collaborator

Domestic

Overseas

Contact us

Headquarter

Address
#5104, Catholic Omnibus Park Building A, The Catholic Univ. of Korea Banpo-daero 222, Secho-gu, Seoul (06591)
TEL
02-2258-7308
FAX
02-537-6586

Research center

Address
2F, 47-3, Banpo-daero 39-gil, Seocho-gu, Seoul (06579)
TEL
02-595-2812
FAX
02-595-2810

About Neornat